Enterprise Value

2.681B

Cash

48.66M

Avg Qtr Burn

-4.969M

Short % of Float

0.52%

Insider Ownership

0.55%

Institutional Own.

56.26%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Setrusumab (UX143) Details
Osteogenesis imperfecta

Phase 2/3

Update

Phase 2

Data readout

Alvelestat (MPH-966) (oral neutrophil elastase inhibitor) Details
Severe alpha-1 antitrypsin deficiency, Lung disease

Phase 2

Update

Etigilimab Details
Ovarian cancer, Cancer

Phase 1b

Update

Phase 1b

Update

Failed

Discontinued